Showing results (1-10 of 243) with videos related to

Sort By:
Pageof 25
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 21, 2020
[COVID-19 Pneumonia]Kenichiro Kudo, Eiki Ichihara
Internal Medicine (Tokyo, Japan)|January 8, 2013
A definite case of (L)-carbocisteine-induced pneumonia with CATCH22 syndromeKenichiro Kudo, Eiki Ichihara, Akiko Hisamoto, et al.
Molecular Cancer Therapeutics|February 28, 2013
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer modelTakashi Ninomiya, Nagio Takigawa, Eiki Ichihara, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2015
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703Kenichiro Kudo, Katsuyuki Hotta, Eiki Ichihara, et al.
Japanese Journal of Clinical Oncology|September 3, 2013
Usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in distinguishing sarcoidosis from recurrent cancer in patients with lymphadenopathy after surgeryDaisuke Minami, Nagio Takigawa, Hiromi Hayakawa, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutationsEiki Ichihara, Katsuyuki Hotta, Nagio Takigawa, et al.
Cancer Discovery|July 9, 2015
Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerEiki Ichihara, Christine M Lovly
Acta Medica Okayama|December 23, 2011
Targeting angiogenesis in cancer therapyEiki Ichihara, Katsuyuki Kiura, Mitsune Tanimoto
Japanese Journal of Clinical Oncology|October 2, 2013
Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto-Sato, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experienceYuka Kato, Katsuyuki Hotta, Nagio Takigawa, et al.
Pageof 25